Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Tectora, a biotech focused on immunology and inflammation therapies, secured $55 million in Series A funding.
Amount Raised
$55 Million
Round Type
Series A
Description
Tectora, a biotech company focused on immunology and inflammation therapies, has closed a Series A funding round of $55 million. The company was formed with support from Schrödinger, a computational chemistry platform. This funding will support Tectora's development of therapies in immunology and inflammation. The news has drawn attention to Schrödinger's role in the biotech ecosystem.
Fundz sees it the moment Tectora raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansTectora raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.